Ionis Pharmaceuticals Reports 55% Revenue Increase

By Ahmed Jameison • Wednesday, October 29 15:40 • Permanent Link

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has reported its financial results for the third quarter ended September 30, 2025. Here are the key highlights:

Revenue: Total revenue for the third quarter of 2025 was $157 million, a 17% increase from the same period in 2024. For the nine months ended September 30, 2025, total revenue increased by 55% to $740 million compared to the same period in 2024.

Operating Expenses: Operating expenses for the third quarter of 2025 were $317 million, up 14% from the same period in 2024. Operating expenses on a non-GAAP basis were $286 million, marking a 14% increase from the third quarter of 2024.

Loss from Operations: The loss from operations for the third quarter of 2025 was $160 million, compared to a loss of $148 million in the same period in 2024. The loss from operations on a non-GAAP basis was $129 million, up from $116 million in the third quarter of 2024.

Product Sales: * Tryngolza® generated net product sales of $32 million in the third quarter of 2025, representing a nearly 70% increase over the prior quarter. In the nine months ended September 30, 2025, tryngolza's net sales amounted to $57 million.

Financial Guidance: Ionis increased its 2025 financial guidance, with total revenue now expected to be in the range of $875-900 million, up from previous guidance of $825-850 million. Tryngolza product sales, net, are now projected to be in the range of $85-95 million, up from the previous guidance of $75-80 million.

Olezarsen: * Olezarsen demonstrated positive topline results in pivotal phase 3 studies for severe hypertriglyceridemia (SHTG), with a statistically significant reduction in fasting triglycerides and acute pancreatitis events. A supplemental new drug application (SNDA) submission is on track for the end of 2025.

Dawnzera™: * Dawnzera (donidalorsen) was approved by the FDA for prophylaxis to prevent attacks of hereditary angioedema (HAE) and has had an encouraging launch.

Zilganersen: * Zilganersen demonstrated positive results in the pivotal study for Alexander disease, positioning Ionis for a first independent neurology launch in 2026.

Financial Position: * As of September 30, 2025, Ionis had cash, cash equivalents, and short-term investments of $2.2 billion.

Following these announcements, the company's shares moved 0.8%, and are now trading at a price of $73.57. For the full picture, make sure to review IONIS PHARMACEUTICALS INC's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.